Hyperion, Medicis deal

Hyperion acquired worldwide rights to Ravicti glycerol phenylbutyrate ( HPN-100) from Medicis' Ucyclyd Pharma Inc. subsidiary. The companies also amended a 2007 deal to give Hyperion an option to acquire worldwide rights to Buphenyl sodium phenylbutyrate and Ammonul in 1H13. Hyperion had an option to acquire rights to Ravicti under the 2007 deal. Terms were not disclosed. ...